Detalhe da pesquisa
1.
High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.
Proc Natl Acad Sci U S A
; 118(22)2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34050021
2.
The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells.
Blood
; 122(6): 922-31, 2013 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23692853
3.
Low frequency of Vγ9Vδ2 T-cells predicts poor survival in newly diagnosed acute myeloid leukemia.
Blood Adv
; 2024 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38788176
4.
Prognostic Immune Effector Signature in Adult Acute Lymphoblastic Leukemia Patients Is Dominated by γδ T Cells.
Cells
; 12(13)2023 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37443727
5.
Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.
J Clin Immunol
; 32(3): 632-46, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22318393
6.
ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.
Blood Adv
; 4(20): 5203-5214, 2020 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33095875
7.
Persistence of natural killer cells with expansion of a hypofunctional CD56-CD16+KIR+NKG2C+ subset in a patient with atypical Janus kinase 3-deficient severe combined immunodeficiency.
J Allergy Clin Immunol
; 131(4): 1230-3, 1233.e1-2, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23069490
8.
Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
Oncotarget
; 10(52): 5493, 2019 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31534634
9.
CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas.
Blood Adv
; 2(15): 1889-1900, 2018 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30087107
10.
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Front Immunol
; 9: 977, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29780393
11.
Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells.
Front Immunol
; 8: 64, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28210257
12.
Editor's Note: ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy.
Cancer Res
; 82(8): 1671, 2022 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35425966
13.
NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML.
Oncoimmunology
; 6(12): e1307491, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29209559
14.
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
Oncotarget
; 8(30): 49548-49563, 2017 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28548938
15.
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia.
Front Immunol
; 8: 573, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28611767
16.
BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia.
Oncoimmunology
; 5(10): e1146843, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27853633
17.
ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells.
Eur J Cancer
; 156 Suppl 1: S23-S24, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34649648
18.
Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia.
Front Immunol
; 6: 564, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26594214
19.
ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy.
Cancer Res
; 74(23): 6820-32, 2014 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25297632